HAEMONETICS CORP(HAE)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-27.

HAEMONETICS CORP (HAE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HAE at 51.4/100 on a 32-signal composite quality model, placing it at rank #1,531 of 2,961 stocks — the bottom half of the AI-ranked universe. HAE scores in the top quartile across earnings quality (91.7). Areas of concern include revenue growth (26.5) and institutional flow (30.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HAEMONETICS CORP reports quarterly revenue of $339.4M, net income of $33.0M, free cash flow of $44.4M. Top institutional holders of HAE by reported 13-F value include BlackRock, Neuberger Berman Group, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HAE trades on the NYSE exchange and files with the SEC under CIK 313143. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HAE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HAEMONETICS CORP directly from SEC EDGAR.